Mercy Medical Center in Cedar Rapids Launches Health Robotics' First i.v.STATION ONCO Robot in North America
BOZEN, Sud-Tirol, Italy, Jan 29, 2013 (PR Newswire Europe via COMTEX) --
BOZEN, Sud-Tirol, Italy, January 29, 2013 /PRNewswire/ --
Health Robotics reported today that Mercy Medical Center in Cedar Rapids, Iowa issued today a press release to celebrate the launch of the first i.v.STATION ONCO in North America, and uploaded a video testimonial from Desmond Waters, Director of Pharmacy to: http://www.youtube.com/watch v=r2GGBUHe32Q
"We're pleased that Mercy is the first to launch this advanced technology in the U.S.," said Desmond Waters, Pharmacy Director at Mercy. "The oncology robot is yet another example of Mercy leading the way with world-class cancer care. We provide 11,000 i.v. chemotherapy preparations each year so the benefits of having this precise, state-of-the-art equipment for our patients will be far-reaching."
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "I'm very pleased to see our second-generation i.v.STATION ONCO Robot finally launched in the United States. Mercy Medical Center in Cedar Rapids has been and continues to be an excellent Health Robotics' partner in this endeavor, and Mr. Waters and Mercy's executive management team looks forward to host visits from other world leading Oncology institutions. Health Robotics' second North American installation of i.v.STATION ONCO is currently scheduled for Brigham & Women's Hospital in Boston. Besides its small footprint, speed/throughput, and cost advantages over its competitors, i.v.STATION ONCO is the only Oncology robot that both automatically puts a tamper-evident syringe cap and safely attaches a patient label to chemotherapy and monoclonal antibody therapy IV doses."
Mercy Medical Center's press release continued: "This technology removes the element of human error in mixing chemo drugs and allows for precise mixtures, which increases patient safety. Care providers at the Hall-Perrine Cancer Center will be able to remotely and automatically observe, manage, audit, approve and dispense injectable medications without unnecessary exposure to the drugs. If needed, pharmacy staff can supervise and dispense i.v. medications from locations outside the pharmacy via secure intranet access. In addition to the new oncology robot at the Hall-Perrine Cancer Center, Mercy has the only inpatient pharmacy i.v.STATION robot in Iowa, installed in 2009."
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solution. Health Robotics' second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
For additional information, please contact:
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
[ Back To IBM News 's Homepage ]